Howard Levy

Title: Howard Levy: Innovator in Hemophilia Treatment

Introduction

Howard Levy is a notable inventor based in Hopewell, NJ (US), recognized for his contributions to the field of hemophilia treatment. He holds 2 patents that focus on innovative methods for administering modified polypeptides to improve coagulation in patients with hemophilia B.

Latest Patents

Levy's latest patents include groundbreaking methods for the subcutaneous administration of modified factor IX polypeptides. These methods provide a prophylactic treatment for hemophilia B, allowing for daily or less frequent administration, which results in normal coagulation pharmacokinetics and adequate levels of factor IX. Additionally, he has developed modified factor VII polypeptides for on-demand treatment of acute and episodic bleeding. These modified polypeptides exhibit increased coagulant activity, potency, bioavailability, and prolonged duration when administered subcutaneously.

Career Highlights

Howard Levy is currently associated with Catalyst Biosciences, Inc., where he continues to advance research in hemophilia treatment. His work has significantly impacted the way hemophilia is managed, providing patients with more effective treatment options.

Collaborations

Levy collaborates with esteemed colleagues such as Grant E Blouse and Tom Knudsen, contributing to a dynamic research environment focused on innovative solutions for hemophilia.

Conclusion

Howard Levy's innovative work in the field of hemophilia treatment exemplifies the importance of research and development in improving patient care. His patents and ongoing contributions continue to pave the way for advancements in medical treatments.